Telix Pharmaceuticals Limited (TLX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $10.18: Quality below floor (2.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 11.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing... Read more
Sell if holding. Engine safety override at $10.18: Quality below floor (2.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 11.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 6.2/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Telix Pharmaceuticals Limited
Latest news
- Telix Pharmaceuticals' IPAX-2 Study Of TLX101-Tx Completes Patient Enrolment; Maximum Dose Reached With No Dose-limiti — benzinga May 18, 2026 positive
- Why Is Regeneron Stock Sinking Monday? — benzinga May 18, 2026 negative
- Telix Pharma Enters Into LOI To Pursue Collaborations With EDAP And Profound Medical To Explore Investigational Use Of T — benzinga May 15, 2026 positive
- Telix Pharmaceuticals' TLX250-Px PET/CT Demonstrates High Predictive Accuracy Across All Renal Cancer Subtypes In Phase — benzinga May 4, 2026 positive
- Telix Pharmaceuticals Announces That The Marketing Authorization Application Filed In Europe For TLX101-Px Has Been Vali — benzinga Apr 30, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.18: Quality below floor (2.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 11.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $9.76. Score 6.2/10, moderate confidence.
Take-profit target: $18.19 (+78.9% upside). Prior stop was $9.76. Stop-loss: $9.76.
Quality below floor (2.6 < 4.0); Value-trap signals (2/5): High leverage (D/E 1.7), Material insider selling (7 sells, 0.10% of cap).
Telix Pharmaceuticals Limited trades at a P/E of N/A (forward 42.0). TrendMatrix value score: 7.3/10. Verdict: Sell.
What does Telix Pharmaceuticals Limited do?Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and...
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.